• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过比较肿瘤学从兽医模型中获取推进溶瘤病毒疗法的见解。

Insights from veterinary models for advancing oncolytic virotherapy through comparative oncology.

作者信息

Alkayyal Almohanad A

机构信息

Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.

出版信息

Front Mol Biosci. 2025 May 22;12:1615393. doi: 10.3389/fmolb.2025.1615393. eCollection 2025.

DOI:10.3389/fmolb.2025.1615393
PMID:40475753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12137337/
Abstract

Cancer is a complex disease affecting both humans and animals. Comparative immuno-oncology explores immune responses across species to develop effective cancer therapies. Oncolytic viruses (OVs) serve as both direct tumor-lysing agents and immune stimulants, making them an attractive therapeutic option. This review highlights the role of naturally occurring tumors in animal models for OV-based cancer immunotherapy. We examine immune responses in different species, the latest advancements in OV therapy, and the role of precision medicine in veterinary oncology. Understanding these comparative aspects enhances OV translation from preclinical to clinical applications in both veterinary and human oncology.

摘要

癌症是一种影响人类和动物的复杂疾病。比较免疫肿瘤学探索跨物种的免疫反应以开发有效的癌症治疗方法。溶瘤病毒(OVs)既是直接的肿瘤溶解剂又是免疫刺激剂,使其成为有吸引力的治疗选择。本综述强调了天然肿瘤在基于OV的癌症免疫治疗动物模型中的作用。我们研究了不同物种的免疫反应、OV治疗的最新进展以及精准医学在兽医肿瘤学中的作用。了解这些比较方面可增强OV从临床前到兽医和人类肿瘤学临床应用的转化。

相似文献

1
Insights from veterinary models for advancing oncolytic virotherapy through comparative oncology.通过比较肿瘤学从兽医模型中获取推进溶瘤病毒疗法的见解。
Front Mol Biosci. 2025 May 22;12:1615393. doi: 10.3389/fmolb.2025.1615393. eCollection 2025.
2
OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.儿科大脑中的 OV 调节剂:当前状态、联合策略、局限性和未来方向。
Int J Mol Sci. 2024 May 3;25(9):5007. doi: 10.3390/ijms25095007.
3
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.目前溶瘤病毒作为新型癌症免疫疗法的临床现状和最近的临床前进展。
Front Immunol. 2022 Aug 25;13:953410. doi: 10.3389/fimmu.2022.953410. eCollection 2022.
4
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.溶瘤病毒:癌症免疫治疗的前奏。
BioDrugs. 2019 Oct;33(5):485-501. doi: 10.1007/s40259-019-00367-0.
5
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.免疫病毒疗法:抗体药物与溶瘤病毒联合治疗的作用。
Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022.
6
Cutting both ways: the innate immune response to oncolytic virotherapy.双管齐下:溶瘤病毒治疗的固有免疫反应。
Cancer Gene Ther. 2022 Jun;29(6):629-646. doi: 10.1038/s41417-021-00351-3. Epub 2021 Aug 27.
7
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.肿瘤溶瘤病毒治疗癌症:挑战与优化前景。
Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023.
8
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.阐明活肿瘤溶瘤痘苗和热失活痘苗介导的抗肿瘤免疫的机制。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002569.
9
Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation.溶瘤病毒作为癌症治疗手段:从机制洞察到临床转化
Mol Ther. 2025 May 7;33(5):2217-2228. doi: 10.1016/j.ymthe.2025.03.035. Epub 2025 Mar 25.
10
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.联合溶瘤病毒治疗时 PD-1 阻断的最佳时机。
Semin Cancer Biol. 2022 Nov;86(Pt 3):971-980. doi: 10.1016/j.semcancer.2021.05.019. Epub 2021 May 24.

本文引用的文献

1
Canine, Feline, and Murine Mammary Tumors as a Model for Translational Research in Breast Cancer.犬、猫和鼠类乳腺肿瘤作为乳腺癌转化研究的模型
Vet Sci. 2025 Feb 19;12(2):189. doi: 10.3390/vetsci12020189.
2
Comparative oncology in action: vignettes on immunotherapy development.行动中的比较肿瘤学:免疫疗法发展的案例
Vet Oncol. 2025;2(1):5. doi: 10.1186/s44356-025-00017-4. Epub 2025 Feb 14.
3
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.下一代免疫疗法:推进癌症治疗的临床应用
J Clin Med. 2024 Oct 30;13(21):6537. doi: 10.3390/jcm13216537.
4
Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes.犬类和人类骨肉瘤的大规模比较分析揭示了保守的临床相关肿瘤微环境亚型。
Clin Cancer Res. 2024 Dec 16;30(24):5630-5642. doi: 10.1158/1078-0432.CCR-24-1854.
5
The promise of immunotherapeutic strategies to advance cancer treatment in pet dogs.免疫治疗策略在宠物犬癌症治疗中的应用前景。
J Am Vet Med Assoc. 2024 Oct 11;262(12):1583-1593. doi: 10.2460/javma.24.08.0532. Print 2024 Dec 1.
6
Bovine papillomavirus gene expression and inflammatory pathway activation vary between equine sarcoid tumour subtypes.牛乳头瘤病毒基因表达和炎症途径激活在马肉瘤肿瘤亚型之间存在差异。
Vet Immunol Immunopathol. 2024 Nov;277:110838. doi: 10.1016/j.vetimm.2024.110838. Epub 2024 Oct 1.
7
Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma.犬抗 CD20 单克隆抗体在患有弥漫性大 B 细胞淋巴瘤的犬中的安全性和生物学活性。
J Vet Intern Med. 2024 May-Jun;38(3):1666-1674. doi: 10.1111/jvim.17080. Epub 2024 Apr 25.
8
Therapeutic cancer vaccines: advancements, challenges, and prospects.治疗性癌症疫苗:进展、挑战与展望。
Signal Transduct Target Ther. 2023 Dec 13;8(1):450. doi: 10.1038/s41392-023-01674-3.
9
Feline Injection-Site Sarcoma and Other Adverse Reactions to Vaccination in Cats.猫的注射部位肉瘤和其他与疫苗接种相关的不良反应。
Viruses. 2023 Aug 8;15(8):1708. doi: 10.3390/v15081708.
10
Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology.兽医肿瘤学中免疫疗法的人类生物治疗的潜在前景与风险
Vet Sci. 2023 May 9;10(5):336. doi: 10.3390/vetsci10050336.